Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Family Medicine | Internal Medicine | Critical Care | Emergency Medicine | Nursing | Pulmonology | Anesthesiology & Pain | Journal

Back to Journal Articles

Small Airway Obstruction Heralds Emphysema in COPD

Last Updated: October 26, 2011.

 

Patients with chronic obstructive pulmonary disease have fewer 2.0- to 2.5-mm-diameter airways

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
The number of airways with a diameter of 2 to 2.5 mm is significantly reduced in patients with chronic obstructive pulmonary disease, and the narrowing and disappearance of small-airways precedes emphysematous destruction, according to a study published in the Oct. 27 issue of the New England Journal of Medicine.

WEDNESDAY, Oct. 26 (HealthDay News) -- The number of airways with a diameter of 2 to 2.5 mm is significantly reduced in patients with chronic obstructive pulmonary disease (COPD), and the narrowing and disappearance of small-airways precedes emphysematous destruction, according to a study published in the Oct. 27 issue of the New England Journal of Medicine.

John E. McDonough, from St. Paul's Hospital in Vancouver, Canada, and colleagues investigated the association between small-airway obstruction and emphysematous destruction in 78 patients with various stages of COPD based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) scale. Multidetector computed tomography (CT) was used to compare the number of airways in isolated emphysematous lungs from patients undergoing lung transplantation and donor (control) lungs. The extent of emphysema, the number of terminal bronchioles per milliliter of lung volume, and the minimum diameters and cross-sectional areas of terminal bronchioles were measured using microCT.

The investigators found that the number of 2.0- to 2.5-mm-diameter airways was significantly reduced for patients with GOLD stages 1, 2, 3, or 4 compared to the control samples. The total cross-sectional area and number of terminal bronchioles were reduced by 81 to 99.7 percent and by 72 to 89 percent, respectively, in patients with GOLD stage 4 disease. A comparison of the number and dimensions of terminal bronchioles at varying stages of emphysema indicated loss and narrowing of terminal bronchioles before emphysematous destruction onset in COPD.

"These results show that narrowing and disappearance of small conducting airways before the onset of emphysematous destruction can explain the increased peripheral airway resistance reported in COPD," the authors write.

The study was partially funded by GlaxoSmithKline; several authors disclosed financial relationships with pharmaceutical companies, including GSK.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2011 HealthDay. All rights reserved.


Previous: AACR: Hot Dog Carcinogens and Colon Cancer Link Reassessed Next: qHPV Vaccine Efficacious in Anal Intraepithelial Neoplasia

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.